| Anemia in CKD: Understanding the KDIGO 2025 Clinical Practice Guideline | 04/23/2025 | |
| Hospital Safety During the COVID-19 Pandemic: A Closer Look at Nursing-Sensitive Quality Indicators | 04/21/2025 | |
| The Aryl Hydrocarbon Receptor and Lupus: Diagnostic and Therapeutic Advancements | 04/22/2025 | |
| Managing Lupus: Tailored Strategies for Flares and Fatigue Relief | 04/23/2025 | |
| Rare Kidney Disease: A Parent and Caregiver’s Perspective | 02/17/2025 | |
| The Diagnostic Journey of IgA Nephropathy: Identifying Key Obstacles | 04/16/2025 | |
| Deciphering IgA Nephropathy: Insights into the Diagnostic Process | 04/10/2025 | |
| Advances in IgAN: New Frontiers in Biomarkers and Treatment | 04/14/2025 | |
| Diagnosing IgA Nephropathy: The Role of Immunofluorescence and Immunohistochemistry | 04/10/2025 | |
| Assessing the AMA MAPTM Hypertension Program’s Impact at Rush University Medical Center | 04/20/2025 | |
| Examining a Therapeutic Modality for 2L+ mNSCLC | 04/22/2025 | |
| Improving CKD Patient Outcomes with SGLT2 Inhibitors | 11/17/2024 | |
| Clinical Insights into Higher-Risk MDS: Treatment Goals and Strategies | 04/21/2025 | |
| Insights into the IgAN Patient Journey: From Diagnosis to Treatment | 03/02/2024 | |
| Unpacking Myelofibrosis: Pathogenesis and Management Goals | 04/22/2025 | |
